Corbus Pharmaceuticals Q2 2024 Earnings Report

Corbus Pharmaceuticals EPS Results

• Actual EPS: -$0.90
• Consensus EPS: -$1.19
• Beat/Miss: Beat by +$0.29
• One Year Ago EPS: N/A

Corbus Pharmaceuticals Revenue Results

• Actual Revenue: N/A
• Expected Revenue: N/A
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

Corbus Pharmaceuticals Announcement Details

• Quarter: Q2 2024
• Date: 8/6/2024
• Time: TAS
• Conference Call Date: Tuesday, August 6, 2024
• Conference Call Time: 8:00AM ET

Corbus Pharmaceuticals (NASDAQ:CRBP) (NASDAQ:CRBP) is a clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for patients with rare inflammatory and fibrotic diseases. Headquartered in Norwood, Massachusetts, Corbus applies its expertise in the endocannabinoid system to advance a pipeline of small-molecule drug candidates designed to modulate immune responses and reduce chronic inflammation and fibrosis.

The company’s lead investigational therapy, lenabasum, is an oral, selective cannabinoid type 2 (CB2) receptor agonist. Lenabasum is being evaluated in Phase 3 trials for systemic sclerosis and dermatomyositis, two debilitating autoimmune conditions characterized by inflammation and tissue scarring. Corbus is also advancing additional programs—CRB-601 and CRB-602—aimed at addressing unmet medical needs in conditions where dysregulation of innate immune signaling plays a central role.

Founded in 2006 under its former name, CB Therapeutics, the company rebranded to Corbus Pharmaceuticals in 2013 following its initial public offering. Over the years, Corbus has established research collaborations with academic institutions and clinical centers across North America and Europe. These partnerships support its rigorous clinical trial programs and facilitate access to patient populations affected by rare diseases.

Corbus is led by President and Chief Financial Officer Donald F. McCaffrey, who brings more than two decades of experience in biotechnology finance and operations. The company’s executive team and board of directors comprise seasoned professionals in drug development, regulatory affairs, and commercial strategy, all united by a commitment to bringing new therapies to patients with few treatment options.